Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

2015 Annual Meeting | 2ES.002 - Controversies in Multiple Sclerosis Therapy

Sunday 04/19/15
08:00 AM - 11:00 AM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Extended Seminar
Mark Keegan, MD, FÂ鶹´«Ã½Ó³»­
Participants should be familiar with relative pros and cons of a number of controversies in MS evaluation and therapy.
3.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge
Trainee, General Neurologist, Specialist Neurologist
Case-based, Didactic, Audience Participation
Event Timeline
08:00 AM - 08:20 AM Resolved: Patients with Clinically Isolated Syndrome Should Always Be Treated with MS Therapies
Robert J. Fox, MD, FÂ鶹´«Ã½Ó³»­, Brian G. Weinshenker, MD, FÂ鶹´«Ã½Ó³»­
08:20 AM - 08:30 AM Questions and Answers
08:30 AM - 08:50 AM Resolved: Injectable Therapies Can Be Abandoned as First-line MS Treatments
Mark Keegan, MD, FÂ鶹´«Ã½Ó³»­, Brian G. Weinshenker, MD, FÂ鶹´«Ã½Ó³»­
08:50 AM - 09:00 AM Questions and Answers
09:00 AM - 09:20 AM Resolved: JCV-positive MS Patients Should Discontinue Natalizumab Therapy
Robert J. Fox, MD, FÂ鶹´«Ã½Ó³»­, Mark Keegan, MD, FÂ鶹´«Ã½Ó³»­
09:20 AM - 09:30 AM Questions and Answers
09:30 AM - 09:50 AM Break
09:50 AM - 10:10 AM Resolved: Once Started, MS Therapies Should Be Continued for Life
Robert J. Fox, MD, FÂ鶹´«Ã½Ó³»­, Brian G. Weinshenker, MD, FÂ鶹´«Ã½Ó³»­
10:10 AM - 10:20 AM Questions and Answers
10:20 AM - 10:40 AM Resolved: Patients with MS-related Gait Difficulties Should Be Given a Trial of Dalfampridine Therapy
Mark Keegan, MD, FÂ鶹´«Ã½Ó³»­, Brian G. Weinshenker, MD, FÂ鶹´«Ã½Ó³»­
10:40 AM - 11:00 AM Discussion
Faculty Disclosures
Mark Keegan, MD, FÂ鶹´«Ã½Ó³»­ Dr. Keegan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Keegan has received publishing royalties from a publication relating to health care. Dr. Keegan has received publishing royalties from a publication relating to health care.
Brian G. Weinshenker, MD, FÂ鶹´«Ã½Ó³»­ Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zenas Pharma. Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care.
Robert J. Fox, MD, FÂ鶹´«Ã½Ó³»­ Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AB Science. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Immunic. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siemens. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astoria Biologica. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for InnoCare Pharma. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. The institution of Dr. Fox has received research support from National Institutes of Health. The institution of Dr. Fox has received research support from National MS Society. Dr. Fox has received publishing royalties from a publication relating to health care.